Weekly Research Analysts’ Ratings Changes for Stryker (SYK)

Stryker (NYSE: SYK) recently received a number of ratings updates from brokerages and research firms:

• 1/7/2025 – Stryker had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $425.00 price target on the stock.
• 1/7/2025 – Stryker had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 1/7/2025 – Stryker had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $442.00 price target on the stock.
• 1/1/2025 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 12/18/2024 – Stryker had its price target raised by analysts at Truist Financial Co. from $380.00 to $409.00. They now have a “hold” rating on the stock.
• 12/12/2024 – Stryker had its price target raised by analysts at Needham & Company LLC from $409.00 to $442.00. They now have a “buy” rating on the stock.
• 12/11/2024 – Stryker had its price target raised by analysts at Wells Fargo & Company from $405.00 to $427.00. They now have an “overweight” rating on the stock.
• 12/11/2024 – Stryker had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $425.00 price target on the stock, up previously from $400.00.
• 12/11/2024 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 12/11/2024 – Stryker had its price target raised by analysts at Citigroup Inc. from $411.00 to $450.00. They now have a “buy” rating on the stock.
• 12/2/2024 – Stryker was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $445.00 price target on the stock, up previously from $370.00.
• 11/22/2024 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/14/2024 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Stryker Stock Performance

Shares of SYK stock opened at $355.17 on Wednesday. Stryker Co. has a 12 month low of $294.34 and a 12 month high of $398.20. The firm’s 50 day moving average is $375.25 and its 200 day moving average is $357.42. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $135.40 billion, a P/E ratio of 38.07, a PEG ratio of 2.82 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the previous year, the company earned $2.46 earnings per share. Stryker’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, sell-side analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.95%. Stryker’s payout ratio is presently 36.01%.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by company insiders.

Institutional Trading of Stryker

Hedge funds have recently bought and sold shares of the company. Parnassus Investments LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at $762,798,000. Baltimore Washington Financial Advisors Inc. boosted its position in Stryker by 2.4% during the third quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock valued at $24,089,000 after buying an additional 1,554 shares during the period. Sivik Global Healthcare LLC grew its stake in shares of Stryker by 8.0% during the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock valued at $9,754,000 after buying an additional 2,000 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Stryker by 2.7% in the second quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after buying an additional 16,504 shares during the period. Finally, World Investment Advisors LLC lifted its stake in shares of Stryker by 126.1% in the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after acquiring an additional 4,541 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.